Compare, Analyse Natco Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   ACTAVIS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
ACTAVIS
Dec-18
NATCO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,08013,729-   
Low Rs6719,209-   
Sales per share (Unadj.) Rs592.13,367.7-  
Earnings per share (Unadj.) Rs188.4-1,084.7-  
Cash flow per share (Unadj.) Rs206.3354.9-  
Dividends per share (Unadj.) Rs8.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs833.613,890.1-  
Shares outstanding (eoy) m36.90332.60-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.53.4 43.4%   
Avg P/E ratio x4.6-10.6 -44.0%  
P/CF ratio (eoy) x4.232.3 13.1%  
Price / Book Value ratio x1.10.8 127.2%  
Dividend payout %4.40-   
Avg Mkt Cap Rs m32,3113,814,612 0.8%   
No. of employees `0004.816.9 28.6%   
Total wages/salary Rs m3,2560-   
Avg. sales/employee Rs Th4,522.566,277.4 6.8%   
Avg. wages/employee Rs Th674.00-   
Avg. net profit/employee Rs Th1,439.0-21,348.0 -6.7%   
INCOME DATA
Net Sales Rs m21,8481,120,088 2.0%  
Other income Rs m40421,420 1.9%   
Total revenues Rs m22,2521,141,507 1.9%   
Gross profit Rs m9,28429,352 31.6%  
Depreciation Rs m662478,813 0.1%   
Interest Rs m15464,635 0.2%   
Profit before tax Rs m8,872-492,677 -1.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0125,652 0.0%   
Tax Rs m1,920-6,244 -30.8%   
Profit after tax Rs m6,952-360,781 -1.9%  
Gross profit margin %42.52.6 1,621.6%  
Effective tax rate %21.61.3 1,707.7%   
Net profit margin %31.8-32.2 -98.8%  
BALANCE SHEET DATA
Current assets Rs m21,307459,401 4.6%   
Current liabilities Rs m5,920406,402 1.5%   
Net working cap to sales %70.44.7 1,488.4%  
Current ratio x3.61.1 318.4%  
Inventory Days Days7320 374.0%  
Debtors Days Days10766 160.6%  
Net fixed assets Rs m14,986126,788 11.8%   
Share capital Rs m3690-   
"Free" reserves Rs m30,3530-   
Net worth Rs m30,7604,619,838 0.7%   
Long term debt Rs m01,626,813 0.0%   
Total assets Rs m37,1517,221,859 0.5%  
Interest coverage x58.6-6.6 -885.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.2 379.2%   
Return on assets %19.1-4.1 -466.4%  
Return on equity %22.6-7.8 -289.4%  
Return on capital %29.3-4.8 -606.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m7,3430-   
CASH FLOW
From Operations Rs m4,636400,165 1.2%  
From Investments Rs m-11,155219,839 -5.1%  
From Financial Activity Rs m6,509-686,803 -0.9%  
Net Cashflow Rs m-18-66,466 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 70.95 Rs / USD

Compare NATCO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: LUPIN  FULFORD INDIA  CADILA HEALTHCARE  J.B.CHEMICALS  STRIDES PHARMA SCIENCE  



Today's Market

September Quarter Results, IPO Buzz, and Top Stocks in Action Today(Pre-Open)

On Wednesday, Indian share markets traded rangebound throughout the day and ended marginally higher. The BSE Sensex closed higher by 95 points to end above 39,000-mark.

Related Views On News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

My Top 10 Stocks for Accelerated Profits

Oct 18, 2019

Equitymaster's co-head of research and editor of Microcap Millionaires, Rahul Shah, talks to us about his market-beating system and his 10 best stocks to buy now. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 23, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS